Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Morgan Stanley increased their position by 2,306,181 shares

<< Previous

Bullboard Posts

Next >>

Comment by FredTheVoiceon Nov 16, 2021 10:30am

126 Views

Post# 34131541

RE:Morgan Stanley increased their position by 2,306,181 shares

Hey Thao,

You are right in a way. What you and I, and others would love, is The Caisse, rebuilding a great position, to that 6 000 000 shares they had near the approval of TROGARZO.

But. If I was the Caisse, I would be on the "waiting agenda" right now. With a wide window open: give me something.....

Cancer goes to phase ....II, GO GO GO...... to 6 000 000 M again.

Would you ?

Take care,

FTV.

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism